EMA Eyes Second Half Of 2016 For Public Hearings On Marketed Medicines
This article was originally published in SRA
The European Medicines Agency's pharmacovigilance committee, PRAC, could be ready to start holding public hearings to support the safety review of certain medicines on the market by the second half of this year. The hearings, when in place, will open up the EU's drug assessment process to the public for the first time.
You may also be interested in...
The Canadian authorities have put in place an expedited pathway for authorizing new COVID-19 drugs and vaccines that offers a more agile approach to reviewing data than what was previously allowed.
A new pre-assessment service for COVID-19 clinical trials that was established by the UK medicines regulator to cut down on review times is being extended to a limited number of other kinds of trials.
The European Medicines Agency is developing a strategy to ensure that women have sufficient information to make informed choices about taking medicines during pregnancy and breastfeeding.